Literature DB >> 10670750

A novel mutation of the KAL1 gene in Kallmann syndrome.

Y Izumi1, K Tatsumi, S Okamoto, A Hosokawa, S Ueno, H Fukui, N Amino.   

Abstract

Kallmann syndrome is defined by the association of hypogonadotropic hypogonadism and anosmia, for which three modes of transmission have been described: X-linked, autosomal recessive and autosomal dominant. The KAL1 gene, responsible for the X-linked form of the disease, has been isolated and its intron-exon organization determined. We report sequence analysis using PCR-direct sequencing method of the entire coding region and splice site junctions of the KAL1 gene in three males with Kallmann syndrome. We found a novel mutation in one case and no mutation in the other two cases. The mutation consisted of a C to T substitution in exon 1 converting codon 66 (CAG) encoding glutamine into a termination codon (TAG)/(Q66X). As a consequence of this mutation, the function of the KAL1 protein consisting of 680 amino acids was severely truncated so as to be consistent with Kallmann syndrome. As only this patient had unilateral renal hypoplasia among the three cases, this would suggest the existence of KAL1 gene mutation in this abnormality.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10670750     DOI: 10.1507/endocrj.46.651

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  2 in total

1.  Mapping of a new locus for congenital anomalies of the kidney and urinary tract on chromosome 8q24.

Authors:  Shazia Ashraf; Bethan E Hoskins; Hassan Chaib; Julia Hoefele; Andreas Pasch; Pawaree Saisawat; Friedrich Trefz; Hans W Hacker; Gudrun Nuernberg; Peter Nuernberg; Edgar A Otto; Friedhelm Hildebrandt
Journal:  Nephrol Dial Transplant       Date:  2009-12-10       Impact factor: 5.992

2.  Eight rare urinary disorders in a patient with Kallmann syndrome: A case report.

Authors:  Huining Tian; Zi Yan; You Lv; Lin Sun; Xiaokun Gang; Guixia Wang
Journal:  Medicine (Baltimore)       Date:  2020-10-23       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.